5.01  -0.06 (-1.18%)		01-30 16:00
Open: 4.99 High: 5.2 Volume: 185,115		Pre. Close: 5.07 Low: 4.94 Market Cap: 91(M)

Short term
Mid term
Targets	6-month :	7.58	1-year :	8.85
Resists	First :	6.48	Second :	7.58
Pivot price	5.18
Supports	First :	4.39	Second :	3.09
MAs	MA(5) :	5.15	MA(20) :	4.93
	MA(100) :	8.76	MA(250) :	12.22
MACD	MACD :	0.1	Signal :	0
%K %D	K(14,3) :	34.7	D(3) :	44.7
RSI	RSI(14): 50.8
52-week	High :	21.97	Low :	3.09

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OM ] has closed above bottom band by 33.5%. Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	5.21 - 5.24	5.24 - 5.26
Low:	4.87 - 4.9	4.9 - 4.93
Close:	4.96 - 5.01	5.01 - 5.06

Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

Thu, 29 Jan 2026
Outset Medical, Inc. (OM) Investor Outlook: Is A 133.83% Upside On The Horizon? - DirectorsTalk Interviews

Wed, 28 Jan 2026
OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System - Finviz

Tue, 27 Jan 2026
Outset Medical wins FDA nod for next-gen Tablo hemodialysis system - MassDevice

Tue, 27 Jan 2026
Outset Medical Secures FDA Clearance For Next-Generation Tablo Hemodialysis System - Nasdaq

Tue, 27 Jan 2026
Outset Medical (OM) Gains FDA Clearance for Advanced Tablo Platf - GuruFocus

Tue, 27 Jan 2026
Outset Medical’s Tablo dialysis system meets FDA cybersecurity standards - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	18 (M)
Shares Float	10 (M)
Held by Insiders	2.7 (%)
Held by Institutions	109 (%)
Shares Short	2,330 (K)
Shares Short P.Month	2,120 (K)

EPS	-11.57
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	7.78
Profit Margin	-73.2 %
Operating Margin	-53.8 %
Return on Assets (ttm)	-15.3 %
Return on Equity (ttm)	-92.4 %
Qtrly Rev. Growth	2.7 %
Gross Profit (p.s.)	2.49
Sales Per Share	6.61
EBITDA (p.s.)	-3.57
Qtrly Earnings Growth	0 %
Operating Cash Flow	-53 (M)
Levered Free Cash Flow	-25 (M)

PE Ratio	-0.44
PEG Ratio	0
Price to Book value	0.64
Price to Sales	0.75
Price to Cash Flow	-1.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.